首页> 美国卫生研究院文献>Biomarker Research >Metastatic biomarkers in synovial sarcoma
【2h】

Metastatic biomarkers in synovial sarcoma

机译:滑膜肉瘤转移生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Synovial sarcoma (SS) is an aggressive soft tissue sarcoma (STS) that typically occurs in the extremities near a joint. Metastatic disease is common and usually occurs in the lungs and lymph nodes. Surgical management is the mainstay of treatment with chemotherapy and radiation typically used as adjuvant treatment. Although chemotherapy has a positive impact on survival, the prognosis is poor if metastatic disease occurs. The biology of sarcoma invasion and metastasis remain poorly understood. Chromosomal translocation with fusion of the SYT and SSX genes has been described and is currently used as a diagnostic marker, although the full impact of the fusion is unknown. Multiple biomarkers have been found to be associated with SS and are currently under investigation regarding their pathways and mechanisms of action. Further research is needed in order to develop better diagnostic screening tools and understanding of tumor behavior. Development of targeted therapies that reduce metastatic events in SS, would dramatically improve patient prognosis.
机译:滑膜肉瘤(SS)是一种侵袭性软组织肉瘤(STS),通常发生在关节附近的四肢。转移性疾病很常见,通常发生在肺部和淋巴结中。手术管理是通常用作辅助治疗的化学疗法和放射疗法的主要手段。尽管化学疗法对生存有积极影响,但如果发生转移性疾病,则预后较差。肉瘤浸润和转移的生物学机制仍知之甚少。 SYT和SSX基因融合的染色体易位已被描述,目前被用作诊断标记,尽管融合的全部影响尚不清楚。已经发现多种生物标志物与SS相关,并且目前正在研究它们的途径和作用机制。为了开发更好的诊断筛查工具和对肿瘤行为的了解,需要进一步的研究。减少SS转移事件的靶向疗法的开发将大大改善患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号